SCHEMBL14825838

SCHEMBL14825838

CCOC(=O)c1ccnc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OPRD1 P41143 3/20 0.55
▸ HRH1 P35367 6/20 0.51
▸ KCNH2 Q12809 5/20 0.51
▸ CYP3A4 P08684 2/20 0.51
▸ USP2 O75604 2/20 0.51
▸ SLC6A2 P23975 2/20 0.51
▸ HRH2 P25021 2/20 0.51
▸ HTR2A P28223 2/20 0.51
▸ SLC6A4 P31645 2/20 0.51
▸ DRD3 P35462 2/20 0.51
▸ HTR2B P41595 2/20 0.51
▸ SLC6A3 Q01959 2/20 0.51
▸ ADORA3 P0DMS8 2/20 0.51
▸ CNR1 P21554 2/20 0.51
▸ OPRK1 P41145 2/20 0.51
▸ GHSR Q92847 2/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP2D6 P10635 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ HPN P05981 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14825403 0.94 OPRD1 (0.58) OPRD1KCNH2LMNAMEN1KMT2A
SCHEMBL14825474 0.93 CACNA2D1 (0.52) OPRD1HRH1KCNH2CYP3A4USP2
SCHEMBL14825424 0.91 OPRD1 (0.55) OPRD1KCNH2MEN1KMT2ACACNA2D1
SCHEMBL14825842 0.91 OPRD1 (0.54) OPRD1KCNH2LMNAMEN1KMT2A
SCHEMBL14825844 0.87 KDM5C (0.55) HRH1KCNH2CYP3A4USP2SLC6A2
SCHEMBL14825515 0.87 OPRD1 (0.51) OPRD1KCNH2CYP3A4USP2CYP1A2
SCHEMBL14825362 0.87 OPRD1 (0.48) OPRD1HRH1KCNH2SLC6A2HTR2A
SCHEMBL14825534 0.85 OPRD1 (0.49) OPRD1KCNH2MEN1KMT2AMAPK1
SCHEMBL14825488 0.84 OPRD1 (0.46) OPRD1KCNH2OPRM1LMNAMEN1
SCHEMBL14825330 0.84 BCHE (0.55) HRH1KCNH2CYP3A4SLC6A2HRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 — — US disclosed
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 — — US disclosed
EP-2578569-B1 HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARM CO LTD (JP) 2015-10-28 — — EP disclosed
EP-2578569-A1 HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA Pharmaceutical Co., Ltd. (JP) 2013-04-10 — — EP disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 — — US disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST HRH2, HRH4, HRH1 OPRD1 129/4885HRH1 3/4885KCNH2 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback